| Issue Date | Title | Author(s) |
| 4-Jan-2023 | First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring <i>NRAS</i> mutations | Wang, Xuan; Luo, Zhiguo; Chen, Jing; Chen, Yu; Ji, Dongmei; Fan, Li; Chen, Ling; Zhao, Qian; Hu, Pei; Sun, Peng; Jia, Zhongwei; Guo, Jun; Si, Lu |
| 20-May-2020 | MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients. | Hu, Xichun; Gong, Jifang; Ji, Dongmei; Shen, Lin; Li, Yufeng; Wang, Mengde; Huang, Yingjie; Xia, Zhenzhong; Lu, Lingmin; Huang, John; Xu, Li; Li, Jenny; Wan, Yuntao; Qian, Xueming |
| Jan-2020 | Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer | Zhang, Jian; Zheng, Hong; Gao, Yunon; Lou, Ge; Yin, Rutie; Ji, Dongmei; Li, Wenhua; Wang, Wei; Xia, Bairong; Wang, Danqing; Hou, Jianmei; Yan, James; Hei, Yongjiang; Zhanh, Zhi-Yi; Milton, Ashley; Wu, Xiaohua |
| Apr-2023 | Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma | Zhang, Qi; Zhang, Jian; Zhong, Haijun; Yuan, Ying; Yang, Lei; Zhang, Qingyuan; Ji, Dongmei; Gong, Jifang; Li, Jing; Yao, Zhenling; Qi, Chuan; Wang, Jianming; Lu, Lingmin; Shi, Michael; Qian, Xueming; Shen, Lin; Li, Jian; Hu, Xichun |
| 15-Nov-2022 | Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma | Song, Yuqin; Kim, Won-Seog; Yoon, Dok-Hyun; Yang, Haiyan; Cao, Junning; Ji, Dongmei; Koh, Youngil; Jing, Hongmei; Eom, Hyeon-Seok; Kwak, Jae-Yong; Lee, Won-Sik; Lee, Jong-Seok; Shin, Ho-Jin; Jin, Jie; Wang, Mei; Li, Jingrun; Zhu, Jun |
| 2018 | Preliminary Results from a Phase 1 Study of HMPL-523, a Highly Selective Syk Inhibitor, in Chinese Patients with Mature B-Cell Lymphomas | Zhu, Jun; Cao, Junning; Qiu, Lugui; Qi, Junyuan; Song, Yuqin; Tu, Meifeng; Ji, Dongmei; Shen, Weina; Sun, Mingyuan; Hua, Ye; Yang, Chen; Yu, Chen; Wang, Jian; Dai, Guangxiu; Su, Weiguo |
| 20-May-2021 | Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study. | Shen, Lin; Gong, Jifang; Zhang, Jian; Ji, Dongmei; Zhong, Haijun; Yuan, Ying; Yang, Lei; Zhang, Qingyuan; Li, Yufeng; Wang, Mengde; Qi, Chuan; Xia, Zhenzhong; Lu, Lingmin; Huang, John; Sun, Ling; Xu, Li; Shi, Michael; Hu, Xichun |
